267 related articles for article (PubMed ID: 27235164)
1. Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK; Kiseleva AA; Ice RJ; Jones BC; Loskutov YV; Matalkah F; Smolkin MB; Marinak K; Livengood RH; Salkeni MA; Wen S; Hazard HW; Layne GP; Walsh CM; Cantrell PS; Kilby GW; Mahavadi S; Shah N; Pugacheva EN
Mol Cancer Ther; 2016 Aug; 15(8):1809-22. PubMed ID: 27235164
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
[No Abstract] [Full Text] [Related]
3. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Do TV; Xiao F; Bickel LE; Klein-Szanto AJ; Pathak HB; Hua X; Howe C; O'Brien SW; Maglaty M; Ecsedy JA; Litwin S; Golemis EA; Schilder RJ; Godwin AK; Connolly DC
Oncogene; 2014 Jan; 33(5):539-49. PubMed ID: 23334327
[TBL] [Abstract][Full Text] [Related]
6. c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer.
Li Y; Li X; Pu J; Yang Q; Guan H; Ji M; Shi B; Chen M; Hou P
Thyroid; 2018 Dec; 28(12):1642-1654. PubMed ID: 30226440
[No Abstract] [Full Text] [Related]
7. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
[TBL] [Abstract][Full Text] [Related]
8. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
[TBL] [Abstract][Full Text] [Related]
9. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Aurora A enhances radiosensitivity in selected lung cancer cell lines.
Liu N; Wang YA; Sun Y; Ecsedy J; Sun J; Li X; Wang P
Respir Res; 2019 Oct; 20(1):230. PubMed ID: 31647033
[TBL] [Abstract][Full Text] [Related]
12. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
13. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
14. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
15. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
16. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
18. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
Yen CC; Chen SC; Hung GY; Wu PK; Chua WY; Lin YC; Yen CH; Chen YC; Wang JY; Yang MH; Chao Y; Chang MC; Chen WM
Int J Oncol; 2019 Oct; 55(4):938-948. PubMed ID: 31485600
[TBL] [Abstract][Full Text] [Related]
19. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]